Increased glycogen synthase kinase-3β mRNA level in the hippocampus of patients with major depression: A study using the Stanley neuropathology consortium integrative database

Psychiatry Investigation

Volumn 7, Issue 3, 2010, Pages 202-207

  Oh, Dong Hoon ^a   Park, Yong Chon ^a   Kim, Seok Hyeon ^a  

^a Hanyang University   (South Korea)

Author keywords

Data mining; Glycogen synthase kinase 3 ; Hippocampus; Major depressive disorder

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; STATHMIN; STATHMIN LIKE 3; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; ENZYME ACTIVITY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MAJOR DEPRESSION; NEUROPATHOLOGY; PROTEIN EXPRESSION;

EID: 77957724723     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2010.7.3.202     Document Type: Article

References (24)

1. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and Phosphorylase kinase. Eur J Biochem 1980;107:519-527.
2. Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D, et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 2006;403:288-293. (Pubitemid 44040958)
3. Hetman M, Cavanaugh JE, Kimelman D, Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 2000;20:2567-2574.
4. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Nad Acad Sci U S A 1996;93:8455-8459.
5. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004;7:387-390.
6. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effert on beta-catenin in mouse hippocampus. Biol Psychiatry 2004;55:781-784.
7. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004;29: 1426-1431.
8. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007;61:240-245. (Pubitemid 46072784)
9. Tsai SJ, Liou YJ, Hong CJ, Yu YW, Chen TJ. Glycogen synthase kinase-3beta gene is assodated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J 2008;8:384-390.
10. Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P, et al. Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry 2009;66:721-728.
11. Shapira M, Licht A, Milman A, Pick CG, Shohami E, Eldar-Finkelman H. Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury. Mol Cell Neurosci 2007;34: 571-577.
12. Silva R, Mesquita AR, Bessa J, Sousa JC, Sotiropoulos I, Leão P, et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neurosdence 2008;152:656-669.
13. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley foundation brain collection and neuropathology consortium. Schizophr Res 2000;44:151-155. (Pubitemid 30411930)
14. Kim S, Webster MJ. Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 2010;15:326-336.
15. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004;161:1957-1966.
16. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006;79:173-189.
17. Andoh T, Lee SY, Chiueh CC. Preconditioning regulation of bd-2 and p66shc by human NOS1 enhances tolerance to oxidative stress. FASEB J 2000;14:2144-2146.
18. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxidty. Nat Rev Neurosci 2007;8:766-775. (Pubitemid 47462116)
19. Zhou QG, Hu Y, Hua Y, Hu M, Luo CX, Han X, et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem 2007;103:1843-1854.
20. Oliveira RM, Guimarães FS, Deakin JF. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008;41:333-341.
21. Mistry SJ, Atweh GF. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med 2002; 69:299-304.
22. Shumyatsky GP, Malleret G, Shin RM, Takizawa S, Tully K, Tsvetkov E, et al. stathmin, a gene enriched in the amygdala, controls both learned and innate fear. Cell 2005;123:697-709.
23. López-Figueroa AL, Norton CS, López-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 2004;55:225-233.
24. Kim S, Webster MJ. Postmortem brain tissue for drug discovery in psychiatric research. Schizophr Bull 2009;35:1031-1033.